Abbott, Tandem Diabetes Care Partner For Glucose-Ketone Sensor for Diabetes Management

Abbott Laboratories (NYSE:ABT) is one of the best stocks to buy for beginners now. On June 10, Tandem Diabetes Care Inc. (NASDAQ:TNDM) announced a new agreement with Abbott to develop and commercialize integrated diabetes solutions. The collaboration will combine Abbott’s future dual glucose-ketone sensor with Tandem’s innovative insulin delivery systems, with the aim of providing more comprehensive management options for individuals with diabetes.

The Abbott sensor, which is currently under development, will feature combined glucose and ketone sensing technology. The primary goal of the integrated sensor is to help people living with diabetes detect early rises in ketone levels, and thereby enable them to take prompt action and potentially avoid life-threatening diabetic ketoacidosis/DKA.

The President and CEO of Tandem Diabetes Care, John Sheridan, stated that integrating Tandem’s advanced insulin delivery systems with Abbott’s future dual glucose-ketone sensor has the potential to empower patients with diabetes to make faster, more informed decisions about their health, which would ultimately lead to improved outcomes.

Abbott Laboratories (NYSE:ABT) discovers, develops, manufactures, and sells health care products worldwide. Tandem Diabetes Care Inc. (NASDAQ:TNDM) designs, develops, and commercializes technology solutions for people living with diabetes.

While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.